Zacks: Scpharmaceuticals Inc (SCPH) Given $23.33 Consensus Price Target by Brokerages

Scpharmaceuticals Inc (NASDAQ:SCPH) has been given an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation.

Analysts have set a 1-year consensus price target of $23.33 for the company and are expecting that the company will post ($0.51) EPS for the current quarter, according to Zacks. Zacks has also assigned Scpharmaceuticals an industry rank of 163 out of 265 based on the ratings given to related companies.

How to Become a New Pot Stock Millionaire

A number of equities research analysts recently weighed in on the company. Zacks Investment Research cut Scpharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. Jefferies Group restated a “buy” rating and set a $26.00 price objective on shares of Scpharmaceuticals in a research note on Wednesday, March 21st.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Bain Capital Public Equity Management LLC purchased a new stake in shares of Scpharmaceuticals during the 4th quarter worth $1,291,000. AWM Investment Company Inc. acquired a new position in Scpharmaceuticals during the 4th quarter valued at about $1,996,000. Monashee Investment Management LLC acquired a new position in Scpharmaceuticals during the 4th quarter valued at about $230,000. Nicholas Investment Partners LP acquired a new position in Scpharmaceuticals during the 4th quarter valued at about $1,500,000. Finally, Bank of New York Mellon Corp acquired a new position in Scpharmaceuticals during the 4th quarter valued at about $414,000. Hedge funds and other institutional investors own 42.03% of the company’s stock.

Shares of NASDAQ SCPH traded down $0.56 during mid-day trading on Wednesday, reaching $10.19. 90,985 shares of the company were exchanged, compared to its average volume of 56,989. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.12 and a quick ratio of 24.12. The stock has a market capitalization of $203.88 and a P/E ratio of -1.27. Scpharmaceuticals has a 1 year low of $10.12 and a 1 year high of $18.17.

Scpharmaceuticals (NASDAQ:SCPH) last issued its quarterly earnings data on Tuesday, March 20th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.27). equities research analysts anticipate that Scpharmaceuticals will post -2.79 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first reported by Week Herald and is the sole property of of Week Herald. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://weekherald.com/2018/04/21/zacks-scpharmaceuticals-inc-scph-given-23-33-consensus-price-target-by-brokerages.html.

About Scpharmaceuticals

scPharmaceuticals Inc, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products. The company's under development products are for heart failure and infectious diseases that include Furoscix for the treatment of worsening or decompensated heart failure outside of the inpatient setting.

Get a free copy of the Zacks research report on Scpharmaceuticals (SCPH)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply